Disruptive Technologies Transforming Upstream Process Intensification For All Modalities

The global biologics pipeline is growing and diversifying, leading to increased demand for manufacturing capacity. As a result, the bioprocessing industry is investing in new technologies to enable efficiency and productivity. One such technology is the XCell^® Alternating Tangential Flow (ATF) System, which has been adopted for perfusion-based upstream intensification.

XCell ATF perfusion technology has been implemented for the bioprocessing of biologics in the last decade to achieve and maintain high viable cell densities. It offers several benefits, including increased cell density, volumetric productivity, and manufacturing flexibility. Additionally, it allows for reduced cost of goods and smaller facility footprints, all while increasing throughput.

This poster explores the XCell ATF System's applications across various process steps and modalities, including monoclonal antibodies, vaccines, plasmid DNA, and cultivated food. It also presents case studies highlighting the intensification of CHO and SF9 cell growth and vaccine manufacturing.

Access the poster to learn more about how XCell ATF technology can help you achieve your process intensification goals.